Driving CAR T-cells forward
Open accessAbstract
The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the treatment of patients with cancer showed modest results, but the impressive outcomes of several trials of CD19-targeted CAR T cells in the treatment of patients with B-cell malignancies have generated an increased enthusiasm for this approach. Important lessons have been derived from clinical trials of CD19-specific CAR T cells, and ongoing clinical trials are testing CAR designs directed at novel targets involved in haematological and solid malignancies. In this Review, we discuss these trials and present strategies that can increase the antitumour efficacy and safety of CAR T-cell therapy. Given the fast-moving nature of this field, we only discuss studies with direct translational application currently or soon-to-be tested in the clinical setting.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CAR T-cell treatment has the benefits and capabilities of cell therapy: innate capacity to target the disease site, potent activity at the action site, capacity to engage the immune system directly, and capacity to multiply in vivo.
“In reality, CAR T-cell treatment emphasizes the benefits and capabilities of cell therapy: the innate capacity to target the illness site, the potent activity of the action site, the capacity to engage the immune system directly, and the capacity to multiply in vivo.324”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [324]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 118 · Cited by 613
Research works printed but not linked: 2
- [9]Lee DW T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 385 517 528 2014 25319501 PMC7065359
- [73]Chang SS Overview of prostate-specific membrane antigen Rev Urol 6 S13 S18 2004 PMC1472940 16985927
- Authors
- Jackson, H. J., Rafiq, S., & Brentjens, R. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Brentjens, Renier J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2016-03-22
- Volume
- 13
- Issue
- 6
- Pages
- 370-383
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC5529102
- OpenAlex
- W2302851559
- Cited by
- 613
- References
- 118
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 60 · 2023: 62 · 2022: 54 · 2021: 66 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 62 · 2016: 22 · 2014: 1
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA138738, P01CA190174, P01CA059350, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, CD19 CAR T cells, B-cell malignancies, hematologic malignancies, solid tumors, automotive design, antitumour efficacy, CAR T cell safety, clinical trials
- MeSH terms
- Antigens, Neoplasm, Chimera, Humans, Lymphocyte Activation, Neoplasm Proteins, Neoplasms, RNA, Messenger, T-Lymphocytes, Cytokines, Immunotherapy, Adoptive, Treatment Outcome, Antigens, CD19, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
